GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Movano Inc (NAS:MOVE) » Definitions » Debt-to-EBITDA

Movano (Movano) Debt-to-EBITDA : -0.01 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Movano Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Movano's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.22 Mil. Movano's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. Movano's annualized EBITDA for the quarter that ended in Dec. 2023 was $-23.94 Mil. Movano's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.01.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Movano's Debt-to-EBITDA or its related term are showing as below:

MOVE' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.97   Med: -0.01   Max: -0.01
Current: -0.01

During the past 6 years, the highest Debt-to-EBITDA Ratio of Movano was -0.01. The lowest was -0.97. And the median was -0.01.

MOVE's Debt-to-EBITDA is ranked worse than
100% of 429 companies
in the Medical Devices & Instruments industry
Industry Median: 1.24 vs MOVE: -0.01

Movano Debt-to-EBITDA Historical Data

The historical data trend for Movano's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Movano Debt-to-EBITDA Chart

Movano Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial - -0.97 - -0.01 -0.01

Movano Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.01 -0.01 -0.01 -0.01

Competitive Comparison of Movano's Debt-to-EBITDA

For the Medical Devices subindustry, Movano's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Movano's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Movano's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Movano's Debt-to-EBITDA falls into.



Movano Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Movano's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.217 + 0) / -29.532
=-0.01

Movano's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.217 + 0) / -23.936
=-0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Movano  (NAS:MOVE) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Movano Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Movano's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Movano (Movano) Business Description

Traded in Other Exchanges
N/A
Address
6800 Koll Center Parkway, Pleasanton, CA, USA, 94566
Movano Inc is a health-focused technology company developing simple, smart, and personalized devices designed to help individuals on their health journey maintain good health today and prevent and manage chronic diseases in the future. It is developing a proprietary platform that uses Radio Frequency (RF) technology. It enables the creation of low-cost and scalable sensors that fit into wearable and other small form factors.
Executives
Jeremy Cogan officer: CFO 6800 KOLL CENTER PARKWAY, PLEASANTON CA 94566
Michael Aaron Leabman director, officer: CEO and President 207 VERITAS CT, SAN RAMON CA 94582
Emily Fairbairn director 10 ORINDA VIEW ROAD, ORINDA CA 94563
John Mastrototaro director 6800 KOLL CENTER PARKWAY, PLEASANTON CA 94566
Brian Cullinan officer: CFO 6800 KOLL CENTER PARKWAY, PLEASANTON CA 94566
Nan Kirsten Forte director 111 EIGHTH AVENUE, NEW YORK NY 10011
Ruben Caballero director C/O RESONANT INC. 10900 STONELAKE BLVD., SUITE 100, OFFICE 02-130, AUSTIN TX 78759
Dvine Irrevocable Trust 10 percent owner 6200 STONERIDGE MALL RD., SUITE 300, PLEASANTON CA 94588
Gregory S Tamkin 10 percent owner 303 RAY STREET, PLEASANTON CA 94566
Dorsey & Whitney Trust Co Llc 10 percent owner 401 EAST EIGHTH STREET, SUITE 319, SIOUX FALLS SD 57103
William Tai-wei Ho 10 percent owner C/O IN8BIO, INC., 79 MADISON AVENUE, NEW YORK NY 10016